期刊文献+

苯甲酸阿格列汀原料药的有关物质及含量测定 被引量:4

Determination of alogliptin benzoate and its related substances
下载PDF
导出
摘要 目的建立RP-HPLC法测定苯甲酸阿格列汀原料药的含量及有关物质。方法采用Thermo ODS-2 HYPERSIL色谱柱(250 mm×4.6 mm,5μm),以乙腈-体积分数为0.1%甲酸水溶液(用三乙胺调p H值为3.0)为流动相,流速为1.0 m L·min^-1,检测波长为278 nm,柱温为30℃。结果在含量测定色谱条件下,阿格列汀在质量浓度8~80 mg·L^-1内与峰面积呈良好线性关系(r=0.999 8,n=5),平均回收率为99.9%(n=9);在有关物质测定色谱条件下,有关物质A、B、C、D和E在质量浓度0.1~2.0 mg·L^-1内与峰面积呈良好的线性关系(r在0.999 6~0.999 8内,n=6);有关物质A、B、D和E含量均小于0.25‰,有关物质C含量小于0.4‰。结论该方法准确、专属性强,为苯甲酸阿格列汀原料药的质量控制提供了依据。 Objective To establish an RP-HPLC method for the determination of alogliptin benzoate and its related substances. Methods The method was performed on a Thermo ODS-2 HYPERSIL column( 250 mm × 4. 6 mm,5 μm) using a mobile phase consisting of acetonitrile as the mobile phase A,0. 1% formic acid( adjust the p H value to 3. 0 with triethylamine) as the mobile phase B. The flowrate was1. 0 m L·min- 1,the detection wavelength was set at 278 nm,and the column temperature was set at 30 ℃.Results For the content determination,a linearity between the area of alogliptin and its concentration was achieved in the range of 8-80 mg·L- 1( r = 0. 999 8,n = 5). The average recovery was 99. 9%( n = 9). For the impurities determination,the standard curves of impurities A-E were linear in the range of 0. 1-2. 0 mg·L- 1( r = 0. 999 6-0. 999 8,n = 6). The contents of impurities A,B,D,E were below0. 25‰,the content of impurity C was below0. 4‰ in the rawmaterial. Conclusions The method is accurate,specific,and provides a reference for the quality control of alogliptin benzoate.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2015年第10期780-785,共6页 Journal of Shenyang Pharmaceutical University
关键词 阿格列汀 有关物质 含量测定 反相高效液相色谱法 alogliptin related substance content determination RP-HPLC
  • 相关文献

参考文献5

  • 1FENG Jun,ZHANG Zhi-yuan,MICHAEL B W,et al.Discovery of alogliptin:Apotent,selective,bioavailabe and efficacious inhibitor of dipeptidyl peptidase IV[J].J Med Chem,2007,50(10):2297-2300.
  • 2RICHARD E P.Alogliptin:A new,highly selective dipeptidyl peptidase4 inhibitor for the treatment of type 2 diabetes[J].Drug Evaluation,2009,10(3):503-512.
  • 3GHATAK S B,PATEL D S,SHANKER N,et al.Alogliptin:A novel molecule for improving glycemic control in type II diabetes mellitus[J].2010,6(6):410-421.
  • 4安富荣,崔岚,王勤.治疗2型糖尿病新药二肽基肽酶-4抑制药阿格列汀[J].中国药师,2012,15(1):116-118. 被引量:15
  • 5刘昭文,吴龙火,王恩军.苯甲酸阿格列汀的合成[J].海峡药学,2011,23(9):214-215. 被引量:18

二级参考文献21

  • 1Feng J,Zhang Z,Wallace MB,et al.Discovery of alogliptin:A potent,selective,bioavailabe,and efficacious inhibitor of dipeptidyl peptidase IV[J].J Med Chem,2007,50(10):2297-2300.
  • 2Serradell N,Rose E,Bolos J.Alogliptin benzoate[J].Drug Future,2008,33(1):7-12.
  • 3Feng J,Gwaltney SL,Stafford JA,et al.Dipeptidyl peptidase inhibitors:WO,2007035629[P].2006,9,15.
  • 4Scott LJ.Alogliptin:a review of its use in the management of type 2 diabetes mellitus[J].Drugs,2010,70 (15):2051-2072.
  • 5Ghatak SB,Patel DS,Shanker N,et al.Alogliptin:a novel molecule for improving glycemic control in type Ⅱ diabetes mellitus[J].Curr Diabetes Rev,2010,6 (6):410-421.
  • 6Karim A,Covington P,Christopher R,et al.Pharmacokinetics of alogliptin when administered with food,metformin,or cimetidine:a twophase,crossover study in healthy subjects[J].Int J Clin Pharmacol Ther,2010,48 (1):46-58.
  • 7Christopher R,Covington P,Davenport M,et al.Pharmacokinetics,pharmacodynamics,and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects[J].Clin Ther,2008,30 (3):513-527.
  • 8Covington P,Christopher R,Davenport M,et al.Pharmacokinetic,pharmacodynamic,and tolerability profiles of the dipeptidyl peptidase4 inhibitor alogliptin:a randomized,double-blind,placebo-controlled,multiple-dose study in adult patients with type 2 diabetes[J].Clin Ther,2008,30 (3):499-512.
  • 9Fleck P,Christopher R,Covington P,et al.Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with type 2 diabetes[J].Diabetes,2008,57 (Suppl.1):143.
  • 10DeFronzo RA,Fleck PR,Wilson CA,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control:a randomized,double-blind,placebo-controlled study[J].Diabetes Care,2008,31 (12):2315-2317.

共引文献28

同被引文献28

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部